|
시장보고서
상품코드
1193135
올란자핀 시장 : 용도별, 투여 경로별, 유통 채널별 - 세계 기회 분석 및 산업 예측(2021-2031년)Olanzapine Market By Application, By Route of Administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031 |
||||||
올란자핀은 비정형 항정신병 약물로 주로 정신 분열증과 양극성 장애의 치료에 사용됩니다.
정제, 주사제, 붕괴 정제의 형태로 제공됩니다. 도파민과 세로토닌의 균형을 잡고인지, 기분, 행동을 강화합니다. 올란자핀은 13세 이상의 성인과 청소년에서 사고장애와 이상한 생각, 삶에 대한 관심의 상실, 강한 감정과 부적절한 감정을 일으키는 정신 질환인 정신분열증의 증상 치료에 사용됩니다. 또한 13세 이상의 성인과 청소년기에서 조병, 비애 및 기타 비정상적인 기분의 에피소드를 일으키는 조울증인 양극성 장애의 치료에도 사용됩니다.
세계보건기구(WHO)는 회원국의 정신건강을 촉진하고 정신장애를 예방하기 위해 정신건강 행동 계획을 권장하고 있습니다. 또한 WHO가 발표한 주요 사실에 따르면 전 세계에서 추정 3억 명이 우울증에 6,000만 명이 양극성 장애를 앓고 있다고 합니다. 불안 장애는 어린이부터 성인까지 이환되는 가장 흔한 정신 질환입니다. 4,400만 명의 미국 성인이 불안 장애의 영향을 받는 것으로 평가되고 있습니다. 불안 장애는 매우 치료하기 쉬운 질병임에도 불구하고 불안 장애로 고통받는 사람들의 약 1/3이 치료를 받고 있습니다. 따라서, 이 시장은 주로 정신질환의 유병률의 상승에 의해 견인되고 있는 것으로 생각된다.
올란자핀의 세계 시장의 성장은 주로 정신 분열증의 세계 유병률의 상승에 의해 초래됩니다. 예를 들어 세계보건기구(WHO)에 따르면 2022년 1월 정신분열증은 전세계 약 2,400만 명, 300명 중 1명(0.32%)을 앓고 있다고 한다. 또한 위생관리 및 예방조치 부족으로 인한 병원내 감염(HAI)의 증가가 시장 성장의 주요 요인이 되고 있습니다. 또한 정신장애인을 위한 진료소의 증가와 의료 인프라의 정비도 시장 확대에 기여하고 있습니다. 그러나 올란자핀의 높은 가격과 부작용은 시장 성장을 방해하고 있습니다. 반대로, 주요 선수들에 의한 시장에서 올란자핀의 제품 승인 증가와 신흥 경제 국가의 높은 성장 가능성은 시장 선수들에게 유리한 기회를 제공할 것으로 예상됩니다. 예를 들어, 2021년 6월, 세계 바이오의약품 회사인 Alkermes plc.는 성인 정신분열증 치료 및 성인 쌍극 I형 장애 치료, 유지 단독 요법 또는 리튬 또는 발프로산 보조 치료로 조 또는 혼합 에피소드의 급성 치료로 LYBALVI (올란자핀과 사미돌 팬)의 미국 식품 의약국 (FDA)을 받았습니다.
목차
제1장 소개
제2장 주요 요약
제3장 시장 개요
- 시장의 정의와 범위
- 주요 조사 결과
- 주요 투자 포켓
- Porter's Five Forces 분석
- 주요 기업의 포지셔닝
- 시장 역학
- 촉진 요인
- 억제 요인
- 기회
- COVID-19 시장에 미치는 영향 분석
제4장 올란자핀 시장 : 용도별
- 개요
- 시장 규모 및 예측
- 정신분열증
- 주요 시장 동향, 성장 요인, 기회
- 시장 규모·예측 : 지역별
- 시장 점유율 분석 : 국가별
- 양극성 장애
- 주요 시장 동향, 성장 요인, 기회
- 시장 규모·예측 : 지역별
- 시장 점유율 분석 : 국가별
- 기타
- 주요 시장 동향, 성장 요인, 기회
- 시장 규모·예측 : 지역별
- 시장 점유율 분석 : 국가별
제5장 올란자핀 시장 : 투여 경로별
- 개요
- 시장 규모 및 예측
- 경구
- 주요 시장 동향, 성장 요인, 기회
- 시장 규모·예측 : 지역별
- 시장 점유율 분석 : 국가별
- 비경구
- 주요 시장 동향, 성장 요인, 기회
- 시장 규모·예측 : 지역별
- 시장 점유율 분석 : 국가별
제6장 올란자핀 시장 : 유통 채널별
- 개요
- 시장 규모·예측
- 병원 약국
- 주요 시장 동향, 성장 요인과 기회
- 시장 규모·예측 : 지역별
- 시장 점유율 분석 : 국가별
- 약국, 소매 약국
- 주요 시장 동향, 성장 요인, 기회
- 시장 규모·예측 : 지역별
- 시장 점유율 분석 : 국가별
- 온라인 제공자
- 주요 시장 동향, 성장 요인, 기회
- 시장 규모·예측 : 지역별
- 시장 점유율 분석 : 국가별
제7장 올란자핀 시장 : 지역별
- 개요
- 시장 규모·예측
- 북미
- 주요 동향과 기회
- 북미의 시장 규모·예측 : 용도별
- 북미 시장 규모·예측 : 투여 경로별
- 북미 시장 규모·예측 : 유통 채널별
- 북미 시장 규모·예측 : 국가별
- 미국
- 캐나다
- 멕시코
- 유럽
- 주요 동향과 기회
- 유럽의 시장 규모·예측 : 용도별
- 유럽 시장 규모·예측 : 투여 경로별
- 유럽 시장 규모·예측 : 유통 채널별
- 유럽 시장 규모·예측 : 국가별
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 기타 유럽 지역
- 아시아태평양
- 주요 동향과 기회
- 아시아태평양의 시장 규모·예측 : 용도별
- 아시아태평양지역의 시장 규모·예측 : 투여경로별
- 아시아태평양의 시장 규모·예측 : 유통 채널별
- 아시아태평양의 시장 규모·예측 : 국가별
- 일본
- 중국
- 인도
- 호주
- 한국
- 기타 아시아태평양
- LAMEA
- 주요 동향과 기회
- LAMEA의 시장 규모·예측 : 용도별
- LAMEA의 시장 규모·예측 : 투여경로별
- LAMEA의 시장 규모·예측 : 유통채널별
- LAMEA의 시장 규모·예측 : 국가별
- 브라질
- 사우디아라비아
- 남아프리카 공화국
- 기타 LAMEA
제8장 기업 정세
- 소개
- 주요 성공 전략
- 주요 10개사의 제품 매핑
- 경쟁 대시보드
- 경합의 히트 맵
- 주요 발전
제9장 기업 프로필
- Alkermes, Inc.
- apotex inc.
- Aurobindo Pharma Ltd
- Eli Lilly and Company
- Dr. Reddy's Laboratories Ltd.
- Sun Pharmaceutical Industries Limited
- 토렌트그룹
- Teva Pharmaceutical Industries Limited
- Novartis AG
- Viatris
Olanzapine is an atypical antipsychotic drug, primarily used to treat schizophrenia and bipolar disorder. It is available in the form of a tablet, injectable, and a disintegrating tablet. It balances dopamine and serotonin to enhance cognition, mood, and behavior. Olanzapine is used to treat the symptoms of schizophrenia, which is a mental condition that causes disturbed or strange thinking, loss of interest in life, and strong or inappropriate emotions, in adults and teenagers 13 years of age and older. It is also used to treat bipolar disorder, which is a manic-depressive disorder, a condition that produces episodes of mania, sadness, and other abnormal moods, in adults and adolescents 13 years of age and older.
World Health Organization (WHO) has recommended mental health action plan to promote mental health and prevent mental disorders in the member states. In addition, according to the key facts published by the WHO, an estimated 300 million people are affected by depression, and 60 million people are affected by bipolar disorder, across the globe. Anxiety disorders are the most communal psychiatric illnesses affecting children and adults. It is evaluated that 44 million American grown-ups experience ill effects of uneasiness issue. Merely, about one-third of those suffering from an anxiety disorder receive treatment, even though the disorders are highly treatable. Therefore, it is indicated that the market is majorly driven by rise in prevalence of mental disorders.
The growth of global olanzapine market is majorly driven by rise in prevalence of schizophrenia globally. For instance, in January 2022, according to World Health Organization (WHO), schizophrenia affects approximately 24 million people or 1 in 300 people (0.32%) globally. In addition, increase in cases of Hospital Acquired Infections (HAI), owing to lack of sanitation and preventive measures, is a major factor responsible for the market growth. Furthermore, rise in the number of mental disorder clinics and improvement in healthcare infrastructure further contribute in the market growth. However, high cost of olanzapine and side effects of olanzapine hinder the market growth. Conversely, rise in product approvals for olanzapine in market by key players and high growth potential in developing economies are anticipated to provide lucrative opportunities to the market players. For instance, in June 2021, Alkermes plc., a global biopharmaceutical company, received U.S. Food and Drug Administration (FDA) for its LYBALVI (olanzapine and samidorphan) for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate.
The olanzapine market is segmented into application, route of administration, distribution channel, and region. On the basis of application, the market is segregated into schizophrenia, bipolar disorders, and others. By route of administration, the market is segmented into oral and parenteral. On the basis of distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global olanzapine market are Alkermes, Apotex Inc., Aurobindo Pharma, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., Torrent Power Ltd, and Viatris Inc.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the olanzapine market analysis from 2021 to 2031 to identify the prevailing olanzapine market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the olanzapine market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global olanzapine market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Application
- Bipolar Disorder
- Others
- Schizophrenia
By Route of Administration
- Oral
- Parenteral
By Distribution Channel
- Hospital Pharmacies
- Drug stores and Retail Pharmacies
- Online Providers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Alkermes, Inc.
- apotex inc.
- Aurobindo Pharma Ltd
- Eli Lilly and Company
- Dr. Reddy's Laboratories Ltd.
- Sun Pharmaceutical Industries Limited
- Torrent Group
- Teva Pharmaceutical Industries Limited
- Novartis AG
- Viatris
TABLE OF CONTENTS
CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter's five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: OLANZAPINE MARKET, BY APPLICATION
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Schizophrenia
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market share analysis by country
- 4.3 Bipolar Disorder
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market share analysis by country
- 4.4 Others
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market share analysis by country
CHAPTER 5: OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Oral
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market share analysis by country
- 5.3 Parenteral
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market share analysis by country
CHAPTER 6: OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Hospital Pharmacies
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market share analysis by country
- 6.3 Drug stores and Retail Pharmacies
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market share analysis by country
- 6.4 Online Providers
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market share analysis by country
CHAPTER 7: OLANZAPINE MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Application
- 7.2.3 North America Market size and forecast, by Route of Administration
- 7.2.4 North America Market size and forecast, by Distribution Channel
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Key market trends, growth factors and opportunities
- 7.2.5.1.2 Market size and forecast, by Application
- 7.2.5.1.3 Market size and forecast, by Route of Administration
- 7.2.5.1.4 Market size and forecast, by Distribution Channel
- 7.2.5.2 Canada
- 7.2.5.2.1 Key market trends, growth factors and opportunities
- 7.2.5.2.2 Market size and forecast, by Application
- 7.2.5.2.3 Market size and forecast, by Route of Administration
- 7.2.5.2.4 Market size and forecast, by Distribution Channel
- 7.2.5.3 Mexico
- 7.2.5.3.1 Key market trends, growth factors and opportunities
- 7.2.5.3.2 Market size and forecast, by Application
- 7.2.5.3.3 Market size and forecast, by Route of Administration
- 7.2.5.3.4 Market size and forecast, by Distribution Channel
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Application
- 7.3.3 Europe Market size and forecast, by Route of Administration
- 7.3.4 Europe Market size and forecast, by Distribution Channel
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Key market trends, growth factors and opportunities
- 7.3.5.1.2 Market size and forecast, by Application
- 7.3.5.1.3 Market size and forecast, by Route of Administration
- 7.3.5.1.4 Market size and forecast, by Distribution Channel
- 7.3.5.2 France
- 7.3.5.2.1 Key market trends, growth factors and opportunities
- 7.3.5.2.2 Market size and forecast, by Application
- 7.3.5.2.3 Market size and forecast, by Route of Administration
- 7.3.5.2.4 Market size and forecast, by Distribution Channel
- 7.3.5.3 UK
- 7.3.5.3.1 Key market trends, growth factors and opportunities
- 7.3.5.3.2 Market size and forecast, by Application
- 7.3.5.3.3 Market size and forecast, by Route of Administration
- 7.3.5.3.4 Market size and forecast, by Distribution Channel
- 7.3.5.4 Italy
- 7.3.5.4.1 Key market trends, growth factors and opportunities
- 7.3.5.4.2 Market size and forecast, by Application
- 7.3.5.4.3 Market size and forecast, by Route of Administration
- 7.3.5.4.4 Market size and forecast, by Distribution Channel
- 7.3.5.5 Spain
- 7.3.5.5.1 Key market trends, growth factors and opportunities
- 7.3.5.5.2 Market size and forecast, by Application
- 7.3.5.5.3 Market size and forecast, by Route of Administration
- 7.3.5.5.4 Market size and forecast, by Distribution Channel
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Key market trends, growth factors and opportunities
- 7.3.5.6.2 Market size and forecast, by Application
- 7.3.5.6.3 Market size and forecast, by Route of Administration
- 7.3.5.6.4 Market size and forecast, by Distribution Channel
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Application
- 7.4.3 Asia-Pacific Market size and forecast, by Route of Administration
- 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 Japan
- 7.4.5.1.1 Key market trends, growth factors and opportunities
- 7.4.5.1.2 Market size and forecast, by Application
- 7.4.5.1.3 Market size and forecast, by Route of Administration
- 7.4.5.1.4 Market size and forecast, by Distribution Channel
- 7.4.5.2 China
- 7.4.5.2.1 Key market trends, growth factors and opportunities
- 7.4.5.2.2 Market size and forecast, by Application
- 7.4.5.2.3 Market size and forecast, by Route of Administration
- 7.4.5.2.4 Market size and forecast, by Distribution Channel
- 7.4.5.3 India
- 7.4.5.3.1 Key market trends, growth factors and opportunities
- 7.4.5.3.2 Market size and forecast, by Application
- 7.4.5.3.3 Market size and forecast, by Route of Administration
- 7.4.5.3.4 Market size and forecast, by Distribution Channel
- 7.4.5.4 Australia
- 7.4.5.4.1 Key market trends, growth factors and opportunities
- 7.4.5.4.2 Market size and forecast, by Application
- 7.4.5.4.3 Market size and forecast, by Route of Administration
- 7.4.5.4.4 Market size and forecast, by Distribution Channel
- 7.4.5.5 South Korea
- 7.4.5.5.1 Key market trends, growth factors and opportunities
- 7.4.5.5.2 Market size and forecast, by Application
- 7.4.5.5.3 Market size and forecast, by Route of Administration
- 7.4.5.5.4 Market size and forecast, by Distribution Channel
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Key market trends, growth factors and opportunities
- 7.4.5.6.2 Market size and forecast, by Application
- 7.4.5.6.3 Market size and forecast, by Route of Administration
- 7.4.5.6.4 Market size and forecast, by Distribution Channel
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Application
- 7.5.3 LAMEA Market size and forecast, by Route of Administration
- 7.5.4 LAMEA Market size and forecast, by Distribution Channel
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Key market trends, growth factors and opportunities
- 7.5.5.1.2 Market size and forecast, by Application
- 7.5.5.1.3 Market size and forecast, by Route of Administration
- 7.5.5.1.4 Market size and forecast, by Distribution Channel
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Key market trends, growth factors and opportunities
- 7.5.5.2.2 Market size and forecast, by Application
- 7.5.5.2.3 Market size and forecast, by Route of Administration
- 7.5.5.2.4 Market size and forecast, by Distribution Channel
- 7.5.5.3 South Africa
- 7.5.5.3.1 Key market trends, growth factors and opportunities
- 7.5.5.3.2 Market size and forecast, by Application
- 7.5.5.3.3 Market size and forecast, by Route of Administration
- 7.5.5.3.4 Market size and forecast, by Distribution Channel
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Key market trends, growth factors and opportunities
- 7.5.5.4.2 Market size and forecast, by Application
- 7.5.5.4.3 Market size and forecast, by Route of Administration
- 7.5.5.4.4 Market size and forecast, by Distribution Channel
CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
CHAPTER 9: COMPANY PROFILES
- 9.1 Alkermes, Inc.
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 apotex inc.
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 Aurobindo Pharma Ltd
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 Eli Lilly and Company
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Dr. Reddy's Laboratories Ltd.
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 Sun Pharmaceutical Industries Limited
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 Torrent Group
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 Teva Pharmaceutical Industries Limited
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Novartis AG
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 Viatris
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
